Type 1 Diabetes — RepurpOS | OpenSourceMedicine

Disease overview

Alterations

121

Molecular (A)

100

Clinical (B–E)

Direct drugs

258

Via biomarker

Natural agents

Natural products

110

Merged ranked

324

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, PubMed NP, ClinicalTrials.gov NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Essentially zero for established T1DM (honeymoon phase occurs in 50-60% after diagnosis but lasts 3-12 months then ends); the disease is permanent autoimmune destruction of beta cells

Best-intervention remission

Closed-loop insulin delivery (artificial pancreas systems — Control-IQ, Omnipod 5) achieves 70-80% time-in-range vs 60% with standard therapy; teplizumab (anti-CD3 mAb) delays T1DM onset by 2+ years in at-risk individuals; islet cell transplantation achieves insulin independence in ~44% at 5 years (CITR data)

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Moderate-large — closed-loop approaches are increasingly standard but true insulin independence is rare with any available therapy

Primary barrier

biological + access

Barrier detail: Beta cell regeneration and transplantation face immune rejection barriers (all islet recipients require chronic immunosuppression); closed-loop systems dramatically improve quality of life and glycemic control but require intensive engagement and are expensive; teplizumab (FDA approved 2022) for delay is not a cure

Last SoC change: 2022 — teplizumab (Tzield) FDA approved for Stage 2 T1DM (first immunotherapy to delay progression); 2023 closed-loop systems widely recommended; 2021 Omnipod 5 cleared; ADA continuous glucose monitoring (CGM) recommended for all T1DM 2020; insulin unchanged as backbone since 1921

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005147 · ORPHA: ORPHA:3044

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Type 1 Diabetes Mellitus may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

233

Phase 3: 76, Phase 2: 108, Phase 1: 49

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

121

Actionable

Pipeline Compounds (Top 6)

Darapladib, Fenretinide, Acipimox, Alemtuzumab, Alirocumab, Antilymphocyte Immunoglobulin (Horse)

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

121 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormality of the pancreatic islet cells	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Autoimmunity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Decreased level of 1,5 anhydroglucitol in serum	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Diabetes mellitus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hyperglycemia	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Ketoacidosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Polydipsia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Polyphagia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Polyuria	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
%time in range (70-180 mg/dL)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
AFF3 ALF transcription elongation factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ANG angiogenin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APOBR apolipoprotein B receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BACH2 BACH transcriptional regulator 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Blood pressure	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
CALCR calcitonin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CARMIL1 capping protein regulator and myosin 1 linker 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD226 CD226 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD3E CD3 epsilon subunit of T-cell receptor complex	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKAL1 CDKAL1 threonylcarbamoyladenosine tRNA methylthiotransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CENPW centromere protein W	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4 cytochrome c oxidase associated subunit FA4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4L2 cytochrome c oxidase hypoxia associated subunit FA4L2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTLA4 cytotoxic T-lymphocyte associated protein 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTRB1 chymotrypsinogen B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTRB2 chymotrypsinogen B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTSH cathepsin H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Coefficient of variation (%)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DPP4 dipeptidyl peptidase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FKBP1A FKBP prolyl isomerase 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOXP3 forkhead box P3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FTO FTO alpha-ketoglutarate dependent dioxygenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FUT2 fucosyltransferase 2 (H blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Fatigue	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
GCGR glucagon receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLIS3 GLIS family zinc finger 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLP1R glucagon like peptide 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPD2 glycerol-3-phosphate dehydrogenase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HNF1A HNF1 homeobox A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HbA1c	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	LOINC
HbA1c Levels	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	LOINC
Hemoglobin A1c (HbA1c)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	LOINC
IFIH1 interferon induced with helicase C domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IGF2BP2 insulin like growth factor 2 mRNA binding protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL10 interleukin 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RA interleukin 2 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL7R interleukin 7 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
INS insulin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
INSR insulin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ITPR3 inositol 1,4,5-trisphosphate receptor type 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KCNQ1 potassium voltage-gated channel subfamily Q member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND2 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND3 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4L mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND5 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA1 NADH:ubiquinone oxidoreductase subunit A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA10 NADH:ubiquinone oxidoreductase subunit A10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA11 NADH:ubiquinone oxidoreductase subunit A11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA12 NADH:ubiquinone oxidoreductase subunit A12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA13 NADH:ubiquinone oxidoreductase subunit A13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA2 NADH:ubiquinone oxidoreductase subunit A2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA3 NADH:ubiquinone oxidoreductase subunit A3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA5 NADH:ubiquinone oxidoreductase subunit A5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA6 NADH:ubiquinone oxidoreductase subunit A6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA7 NADH:ubiquinone oxidoreductase subunit A7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA8 NADH:ubiquinone oxidoreductase subunit A8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA9 NADH:ubiquinone oxidoreductase subunit A9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAB1 NADH:ubiquinone oxidoreductase subunit AB1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF1 NADH:ubiquinone oxidoreductase complex assembly factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF2 NADH:ubiquinone oxidoreductase complex assembly factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF3 NADH:ubiquinone oxidoreductase complex assembly factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF4 NADH:ubiquinone oxidoreductase complex assembly factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB1 NADH:ubiquinone oxidoreductase subunit B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB10 NADH:ubiquinone oxidoreductase subunit B10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB11 NADH:ubiquinone oxidoreductase subunit B11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB2 NADH:ubiquinone oxidoreductase subunit B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB3 NADH:ubiquinone oxidoreductase subunit B3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB4 NADH:ubiquinone oxidoreductase subunit B4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB5 NADH:ubiquinone oxidoreductase subunit B5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB6 NADH:ubiquinone oxidoreductase subunit B6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB7 NADH:ubiquinone oxidoreductase subunit B7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB8 NADH:ubiquinone oxidoreductase subunit B8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB9 NADH:ubiquinone oxidoreductase subunit B9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFC1 NADH:ubiquinone oxidoreductase subunit C1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFC2 NADH:ubiquinone oxidoreductase subunit C2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS2 NADH:ubiquinone oxidoreductase core subunit S2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS3 NADH:ubiquinone oxidoreductase core subunit S3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS4 NADH:ubiquinone oxidoreductase subunit S4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS5 NADH:ubiquinone oxidoreductase subunit S5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS6 NADH:ubiquinone oxidoreductase subunit S6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS7 NADH:ubiquinone oxidoreductase core subunit S7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS8 NADH:ubiquinone oxidoreductase core subunit S8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV2 NADH:ubiquinone oxidoreductase core subunit V2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV3 NADH:ubiquinone oxidoreductase subunit V3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Nadirs analysis of blood glucose during the night (value reached)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	LOINC
Number of hospitalizations and emergency department admissions	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PCLO piccolo presynaptic cytomatrix protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PGM1 phosphoglucomutase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTPN2 protein tyrosine phosphatase non-receptor type 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTPN22 protein tyrosine phosphatase non-receptor type 22	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Pulmonary function (Forced vital capacity (FVC))	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Quality of Life	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
RAMP1 receptor activity modifying protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RAMP2 receptor activity modifying protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RPS26 ribosomal protein S26	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SH2B3 SH2B adaptor protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SIRPG signal regulatory protein gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC5A1 solute carrier family 5 member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC5A2 solute carrier family 5 member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SUOX sulfite oxidase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TCF7L2 transcription factor 7 like 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TYK2 tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Total daily dose of insulin	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	LOINC
UBASH3A ubiquitin associated and SH3 domain containing A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VDR vitamin D receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ZFP36L1 ZFP36 like 1 zinc finger CCCH-type	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ACETAZOLAMIDE	None	Gene-targeted
AMPHETAMINE	None	Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BLINATUMOMAB	antibody	Gene-targeted
CALCITONIN		Gene-targeted
CALCITONIN HUMAN	agonist	Gene-targeted
CALCITONIN SALMON	agonist	Gene-targeted
CARBACHOL	None	Gene-targeted
CATUMAXOMAB	antibody; modulator	Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
DIAZEPAM	None	Gene-targeted
DICHLORPHENAMIDE	None	Gene-targeted
DIETHYLSTILBESTROL	None	Gene-targeted
ELRANATAMAB	binder	Gene-targeted
EPCORITAMAB	binder	Gene-targeted
EPIRUBICIN	None	Gene-targeted
ETHOXZOLAMIDE	None	Gene-targeted
FLUMAZENIL	None	Gene-targeted
GLOFITAMAB	binder	Gene-targeted
IMIPRAMINE	None	Gene-targeted
INDAPAMIDE	None	Gene-targeted
INDOMETHACIN	None	Gene-targeted
ISOSORBIDE DINITRATE	None	Gene-targeted
MAFENIDE	None	Gene-targeted
MECAMYLAMINE	None	Gene-targeted
METHAZOLAMIDE	None	Gene-targeted
METHOXSALEN	None	Gene-targeted
METOPROLOL	None	Gene-targeted
MIANSERIN	None	Gene-targeted
MOSUNETUZUMAB	binder	Gene-targeted
MUROMONAB-CD3	antibody; inhibitor	Gene-targeted
NALIDIXIC ACID	None	Gene-targeted
NICOTINE	None	Gene-targeted
NORFLOXACIN	None	Gene-targeted
OFLOXACIN	None	Gene-targeted
PHENYTOIN	None	Gene-targeted
PRAMLINTIDE	agonist	Gene-targeted
PRAMLINTIDE ACETATE	agonist	Gene-targeted
PRAZOSIN	None	Gene-targeted
SALMON CALCITONIN	agonist	Gene-targeted
SIROLIMUS	None	Gene-targeted
SITAGLIPTIN		Gene-targeted
SULBACTAM	None	Gene-targeted
TACROLIMUS ANHYDROUS	None	Gene-targeted
TALQUETAMAB	binder	Gene-targeted
TARLATAMAB	binder	Gene-targeted
TAZOBACTAM	None	Gene-targeted
TECLISTAMAB	binder	Gene-targeted
TEPLIZUMAB	other/unknown	Gene-targeted
TROGLITAZONE	None	Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
SIROLIMUS	Small molecule	Approved	Strong	105	8 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT01309022 — Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) (NO_LONGER_AVAILABLE) NCT00464555 — Strategies to Improve Islet Survival (COMPLETED) PHASE2 NCT00286624 — Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation (COMPLETED) PHASE1, PHASE2 NCT00708604 — Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes (COMPLETED) PHASE1 NCT00706420 — Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen (ACTIVE_NOT_RECRUITING) PHASE1 NCT00533442 — Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients (COMPLETED) PHASE2 NCT00160732 — Allogenic Islet Cell Transplantation (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT00679042 — Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (ACTIVE_NOT_RECRUITING) PHASE3 Published literature Clinical trial publication Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005) Clinical trial publication Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen (The New England journal of medicine, 2000) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Approved	Strong	105	8 trials View evidence Registry trials NCT01309022 — Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) (NO_LONGER_AVAILABLE) NCT00464555 — Strategies to Improve Islet Survival (COMPLETED) PHASE2 NCT00708604 — Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes (COMPLETED) PHASE1 NCT00706420 — Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen (ACTIVE_NOT_RECRUITING) PHASE1 NCT00533442 — Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients (COMPLETED) PHASE2 NCT00679042 — Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (ACTIVE_NOT_RECRUITING) PHASE3 NCT00309231 — Clinical Islet Transplantation Using the Edmonton Protocol (WITHDRAWN) NCT00789308 — Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE	Small molecule	Approved	Strong	100	2 trials 1 Trial pubs View evidence Registry trials NCT06981234 — Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial (RECRUITING) PHASE2 NCT05473364 — Acetazolamide in Persons With Type 1 Diabetes - Dose Finding (COMPLETED) PHASE1, PHASE2 Published literature Clinical trial publication Changes in cerebral blood flow detected by SPECT in type 1 and type 2 diabetic patients (Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CALCITONIN Repurposing	Small molecule	Approved	Strong	95	7 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CALCITONIN HUMAN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
CALCITONIN SALMON Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CATUMAXOMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ELRANATAMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
EPCORITAMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GLOFITAMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MOSUNETUZUMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
MUROMONAB-CD3 Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT01123083 — Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2 (COMPLETED) PHASE3 NCT00129259 — Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (COMPLETED) PHASE2 NCT00920582 — Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus (TERMINATED) PHASE3 NCT07610213 — Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes (NOT_YET_RECRUITING) PHASE1 NCT00946257 — Subcutaneous Administration of Otelixizumab to T1DM Patients (COMPLETED) PHASE1 NCT04270942 — At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension) (COMPLETED) PHASE2 NCT01210664 — T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs (COMPLETED) PHASE1 NCT04598893 — Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) (ACTIVE_NOT_RECRUITING) CT.gov search · Cochrane · PubMed	DGIdb	—
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT07522866 — Thrive With Type 1 Diabetes 2026 (RECRUITING) NA CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAMLINTIDE Repurposing	Small molecule	Approved	Strong	95	8 trials 8 Trial pubs 6 RCT View evidence Registry trials NCT05199714 — A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes (COMPLETED) NA NCT00790699 — Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port (TERMINATED) NA NCT00489645 — Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide (COMPLETED) NA NCT00229658 — An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes (COMPLETED) NCT01269047 — Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (COMPLETED) PHASE4 NCT00502138 — A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes (COMPLETED) PHASE4 NCT01434862 — Pramlintide Combined With Model Predictive Control Algorithm (TERMINATED) NA NCT04972175 — Safety and Efficacy of BC LisPram (UNKNOWN) PHASE1 Published literature Clinical trial publication Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy (Postgraduate medicine, 2013) Clinical trial publication Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes (The AAPS journal, 2013) Clinical trial publication Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? (The Journal of clinical endocrinology and metabolism, 2010) Clinical trial publication Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2009) Clinical trial publication Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus (Pediatric diabetes, 2009) Randomized controlled trial Properties of pramlintide and insulin upon mixing (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005) Randomized controlled trial Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial (Diabetic medicine : a journal of the British Diabetic Association, 2004) CT.gov search · Cochrane · PubMed	DGIdb	—
PRAMLINTIDE ACETATE Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT05199714 — A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes (COMPLETED) NA NCT00790699 — Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port (TERMINATED) NA NCT00489645 — Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide (COMPLETED) NA NCT00229658 — An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes (COMPLETED) NCT01269047 — Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (COMPLETED) PHASE4 NCT00502138 — A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes (COMPLETED) PHASE4 NCT01434862 — Pramlintide Combined With Model Predictive Control Algorithm (TERMINATED) NA NCT04972175 — Safety and Efficacy of BC LisPram (UNKNOWN) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SALMON CALCITONIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SITAGLIPTIN Repurposing	Small molecule	Approved	Strong	95	8 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT01718093 — A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes (COMPLETED) PHASE4 NCT00978796 — Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes (COMPLETED) PHASE4 NCT00813228 — Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals (COMPLETED) PHASE1 NCT02749032 — Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion (COMPLETED) PHASE1 NCT01441232 — A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics (COMPLETED) PHASE1 NCT04409795 — Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study (COMPLETED) PHASE2, PHASE3 NCT01099618 — Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment (COMPLETED) PHASE4 NCT00749190 — BI 10773 add-on to Metformin in Patients With Type 2 Diabetes (COMPLETED) PHASE2 Published literature Clinical trial publication Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study (Diabetes, obesity & metabolism, 2015) Clinical trial publication C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus (JAMA, 2009) CT.gov search · Cochrane · PubMed	DGIdb	—
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TALQUETAMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
TARLATAMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TECLISTAMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
TEPLIZUMAB Repurposing	Small molecule	Approved	Strong	95	8 trials 5 Cochrane 5 Meta-analysis View evidence Registry trials NCT06338553 — GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab (RECRUITING) EARLY_PHASE1 NCT03751007 — A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) (COMPLETED) PHASE1, PHASE2 NCT07088068 — A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes (RECRUITING) PHASE3 NCT00806572 — Treatment With hOKT3gamma1(Ala-Ala) in T1DM (TERMINATED) PHASE2 NCT07260110 — A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States (RECRUITING) NCT00129259 — Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (COMPLETED) PHASE2 NCT01189422 — Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes (TERMINATED) PHASE1 NCT00920582 — Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus (TERMINATED) PHASE3 Published literature Cochrane review Immunotherapy as a treatment for type 1 diabetes mellitus in children and young adults: A comprehensive systematic review and meta-analysis (PloS one, 2025) Cochrane review Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis (World journal of diabetes, 2024) Cochrane review Effect of Immunotherapy on C-peptide Levels in Patients With Type I Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials (Cureus, 2024) Cochrane review Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials (Diabetes, obesity & metabolism, 2024) Cochrane review Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression (Diabetes, obesity & metabolism, 2023) Meta-analysis Efficacy of teplizumab for treatment of type 1 diabetes: A meta-analysis of randomized controlled trials (Diabetes/metabolism research and reviews, 2024) Meta-analysis Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes (Recent advances in inflammation & allergy drug discovery, 2023) CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACIPIMOX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALEMTUZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALIROCUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BALAGLITAZONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BASILIXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CADISEGLIATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DACLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DASIGLUCAGON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEXTROSE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIAPEP-277	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIMETHYL FUMARATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOMPERIDONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FARGLITAZAR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FINERENONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLUCAGON	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLUTAMATE DECARBOXYLASE 2	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLUTAMIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICODEXTRIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN ASPART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN DEGLUDEC	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN EFSITORA ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN GLULISINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN, ISOPHANE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN ICODEC	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN LISPRO	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN PEGLISPRO	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN PORK	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN SUSP ISOPHANE BEEF	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN, ISOPHANE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IPRAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ITOLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IXMYELOCEL-T	Cell therapy	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANSOPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METOCLOPRAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIGLITOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OMEPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OTELIXIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PHYSIONEAL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRAMLINTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRAMLINTIDE ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROTAMINE SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYRIDOXINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RAGAGLITAZAR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RAMIPRIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REPARIXIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RUBOXISTAURIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SAXAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SITAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TASPOGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TELMISARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TESAGLITAZAR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
THIAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VERAPAMIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VILDAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN B COMPLEX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN B12	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZIMISLECEL	Cell therapy	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABATACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABROCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALAGEBRIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALBIGLUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALEFACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALUMINUM HYDROXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMITRIPTYLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-1656	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BCG LIVE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BCG VACCINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELATACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMIPARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRIVEKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BROMOCRIPTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMICINAL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANAKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARVEDILOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CBX-129801	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLORTHALIDONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CINNAMON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COLCHICINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXTRAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXTRAN SULFATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXTRAN SULFATE SODIUM (5000 MW)	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DULAGLUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFLORNITHINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EXENATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EZETIMIBE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FREXALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GAMMA-AMINOBUTYRIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANCICLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GASTRIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEVOKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GLYBURIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GOLIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYALURONIDASE (HUMAN RECOMBINANT)	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOVAMENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMCY-0098	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISCALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IXEKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LADARIXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENOGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LISDEXAMFETAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LISOFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MBX-2982	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLDOPA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLPHENIDATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MYCOPHENOLATE MOFETIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NBI-6024	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NNC0114-0006	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PANCREATIC POLYPEPTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PANTOPRAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGFILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLECONARIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REMOGLIFLOZIN ETABONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REZPEGALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RILPARENCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RITLECITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIPLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SPERGUALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEGOPRUBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOCILIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TROFINETIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TZP-102	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
USTEKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VICASINABIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VOLAGIDEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HUMAN CALCITONIN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ADALIMUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ADOMEGLIVANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALPRAZOLAM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ATAZANAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AUTOLOGOUS CORD BLOOD	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BTI-410	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BUTYRIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL569766	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DENOSUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DICHLOROACETIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMRICASAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERYTHROMYCIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EVEROLIMUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FLUOXETINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FRUCTOSE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GLUCAGON-LIKE PEPTIDE 1	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYALURONIDASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INSULIN TREGOPIL	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IOHEXOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LIXISENATIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METRELEPTIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-2640	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MOXIFLOXACIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OREMEPERMIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ORNITHINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PAMREVLUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PANCREATIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PHENTOLAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PITOLISANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PLERIXAFOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PROPRANOLOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RECOMBINANT HUMAN KALLIKREIN-1	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RILONACEPT	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SOMATOSTATIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SOMATROPIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SUBSTANCE P	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TAURINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TERBUTALINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIFENAZOXIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VEDOLIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZALFERMIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ADENOSINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALANINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AVEXITIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETA CAROTENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CANDESARTAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CARBAMAZEPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CARNITINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLOTRIMAZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CO-TRIMOXAZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
COLESEVELAM HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DARBEPOETIN ALFA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DASIGLUCAGON HYDROCHLORIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIAZOXIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DONISLECEL	Cell therapy	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPINEPHRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPOETIN BETA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUDROCORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLUTAMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GRC-15300	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN DETEMIR	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN GLARGINE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOMEFOLIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LINAGLIPTIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LIPOIC ACID, ALPHA	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MECASERMIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MYCOPHENOLIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OXYTOCIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SELENIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SOTAGLIFLOZIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SPIRONOLACTONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TEPLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIMETHOPRIM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VALGANCICLOVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VITAMIN E	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACIPIMOX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALEMTUZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALIROCUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BALAGLITAZONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BASILIXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CADISEGLIATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DACLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DASIGLUCAGON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEXTROSE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIAPEP-277	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIMETHYL FUMARATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOMPERIDONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FARGLITAZAR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FINERENONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLUCAGON	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLUTAMATE DECARBOXYLASE 2	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLUTAMIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICODEXTRIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN ASPART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN DEGLUDEC	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN EFSITORA ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN GLULISINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN, ISOPHANE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN ICODEC	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN LISPRO	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN PEGLISPRO	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN PORK	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN SUSP ISOPHANE BEEF	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN, ISOPHANE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IPRAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ITOLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IXMYELOCEL-T	Cell therapy	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANSOPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METOCLOPRAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIGLITOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OMEPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OTELIXIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PHYSIONEAL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRAMLINTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRAMLINTIDE ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROTAMINE SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYRIDOXINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RAGAGLITAZAR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RAMIPRIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REPARIXIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RUBOXISTAURIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SAXAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIROLIMUS	Small molecule	Phase III	Moderate	80	8 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT01309022 — Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) (NO_LONGER_AVAILABLE) NCT00464555 — Strategies to Improve Islet Survival (COMPLETED) PHASE2 NCT00286624 — Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation (COMPLETED) PHASE1, PHASE2 NCT00708604 — Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes (COMPLETED) PHASE1 NCT00706420 — Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen (ACTIVE_NOT_RECRUITING) PHASE1 NCT00533442 — Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients (COMPLETED) PHASE2 NCT00160732 — Allogenic Islet Cell Transplantation (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT00679042 — Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (ACTIVE_NOT_RECRUITING) PHASE3 Published literature Clinical trial publication Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005) Clinical trial publication Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen (The New England journal of medicine, 2000) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
SITAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Phase III	Moderate	80	8 trials View evidence Registry trials NCT01309022 — Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) (NO_LONGER_AVAILABLE) NCT00464555 — Strategies to Improve Islet Survival (COMPLETED) PHASE2 NCT00708604 — Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes (COMPLETED) PHASE1 NCT00706420 — Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen (ACTIVE_NOT_RECRUITING) PHASE1 NCT00533442 — Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients (COMPLETED) PHASE2 NCT00679042 — Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (ACTIVE_NOT_RECRUITING) PHASE3 NCT00309231 — Clinical Islet Transplantation Using the Edmonton Protocol (WITHDRAWN) NCT00789308 — Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
TASPOGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TELMISARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TESAGLITAZAR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
THIAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VERAPAMIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VILDAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN B COMPLEX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN B12	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZIMISLECEL	Cell therapy	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABATACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABROCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACETAZOLAMIDE	Small molecule	Phase II	Emerging	60	2 trials 1 Trial pubs View evidence Registry trials NCT06981234 — Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial (RECRUITING) PHASE2 NCT05473364 — Acetazolamide in Persons With Type 1 Diabetes - Dose Finding (COMPLETED) PHASE1, PHASE2 Published literature Clinical trial publication Changes in cerebral blood flow detected by SPECT in type 1 and type 2 diabetic patients (Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
ALAGEBRIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALBIGLUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALEFACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALUMINUM HYDROXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMITRIPTYLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-1656	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BCG LIVE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BCG VACCINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELATACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMIPARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRIVEKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BROMOCRIPTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMICINAL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANAKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARVEDILOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CBX-129801	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLORTHALIDONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CINNAMON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COLCHICINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXTRAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXTRAN SULFATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXTRAN SULFATE SODIUM (5000 MW)	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DULAGLUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFLORNITHINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EXENATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EZETIMIBE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FREXALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GAMMA-AMINOBUTYRIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANCICLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GASTRIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEVOKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GLYBURIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GOLIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYALURONIDASE (HUMAN RECOMBINANT)	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOVAMENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMCY-0098	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISCALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IXEKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LADARIXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENOGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LISDEXAMFETAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LISOFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MBX-2982	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLDOPA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLPHENIDATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MYCOPHENOLATE MOFETIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NBI-6024	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NNC0114-0006	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PANCREATIC POLYPEPTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PANTOPRAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGFILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLECONARIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REMOGLIFLOZIN ETABONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REZPEGALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RILPARENCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RITLECITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIPLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SPERGUALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEGOPRUBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOCILIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TROFINETIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TZP-102	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
USTEKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VICASINABIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VOLAGIDEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ADOMEGLIVANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALPRAZOLAM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ATAZANAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AUTOLOGOUS CORD BLOOD	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BTI-410	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BUTYRIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL569766	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DENOSUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DICHLOROACETIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMRICASAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERYTHROMYCIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EVEROLIMUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FLUOXETINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FRUCTOSE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GLUCAGON-LIKE PEPTIDE 1	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYALURONIDASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INSULIN TREGOPIL	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IOHEXOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LIXISENATIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METRELEPTIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-2640	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MOXIFLOXACIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OREMEPERMIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ORNITHINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PAMREVLUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PANCREATIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PHENTOLAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PITOLISANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PLERIXAFOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PROPRANOLOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RECOMBINANT HUMAN KALLIKREIN-1	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RILONACEPT	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SOMATOSTATIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SOMATROPIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SUBSTANCE P	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TAURINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TERBUTALINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIFENAZOXIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VEDOLIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZALFERMIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ADENOSINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALANINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AVEXITIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETA CAROTENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CANDESARTAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CARBAMAZEPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CARNITINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLOTRIMAZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CO-TRIMOXAZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
COLESEVELAM HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DARBEPOETIN ALFA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DASIGLUCAGON HYDROCHLORIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIAZOXIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DONISLECEL	Cell therapy	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPINEPHRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPOETIN BETA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUDROCORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLUTAMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GRC-15300	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN DETEMIR	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN GLARGINE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOMEFOLIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LINAGLIPTIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LIPOIC ACID, ALPHA	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MECASERMIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MYCOPHENOLIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OXYTOCIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SELENIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SOTAGLIFLOZIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SPIRONOLACTONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TEPLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIMETHOPRIM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VALGANCICLOVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VITAMIN E	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via ANG	Small molecule	Approved	Strong	95	2 trials 1 Trial pubs View evidence Registry trials NCT06981234 — Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial (RECRUITING) PHASE2 NCT05473364 — Acetazolamide in Persons With Type 1 Diabetes - Dose Finding (COMPLETED) PHASE1, PHASE2 Published literature Clinical trial publication Changes in cerebral blood flow detected by SPECT in type 1 and type 2 diabetic patients (Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
AMPHETAMINE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BICALUTAMIDE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BLINATUMOMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CALCITONIN Repurposing via CALCR	Small molecule	Approved	Strong	95	7 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CALCITONIN HUMAN Repurposing via CALCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
CALCITONIN SALMON Repurposing via CALCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
CARBACHOL Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CATUMAXOMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CIPROFLOXACIN Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIAZEPAM Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ELRANATAMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
EPCORITAMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUMAZENIL Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GLOFITAMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
IMIPRAMINE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAFENIDE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MOSUNETUZUMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
MUROMONAB-CD3 Repurposing via CD3E	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT01123083 — Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2 (COMPLETED) PHASE3 NCT00129259 — Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (COMPLETED) PHASE2 NCT00920582 — Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus (TERMINATED) PHASE3 NCT07610213 — Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes (NOT_YET_RECRUITING) PHASE1 NCT00946257 — Subcutaneous Administration of Otelixizumab to T1DM Patients (COMPLETED) PHASE1 NCT04270942 — At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension) (COMPLETED) PHASE2 NCT01210664 — T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs (COMPLETED) PHASE1 NCT04598893 — Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) (ACTIVE_NOT_RECRUITING) CT.gov search · Cochrane · PubMed	DGIdb	—
NALIDIXIC ACID Repurposing via ANG	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing via ANG	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT07522866 — Thrive With Type 1 Diabetes 2026 (RECRUITING) NA CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NORFLOXACIN Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing via ANG	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
PHENYTOIN Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAMLINTIDE Repurposing via CALCR	Small molecule	Approved	Strong	95	8 trials 8 Trial pubs 6 RCT View evidence Registry trials NCT05199714 — A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes (COMPLETED) NA NCT00790699 — Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port (TERMINATED) NA NCT00489645 — Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide (COMPLETED) NA NCT00229658 — An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes (COMPLETED) NCT01269047 — Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (COMPLETED) PHASE4 NCT00502138 — A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes (COMPLETED) PHASE4 NCT01434862 — Pramlintide Combined With Model Predictive Control Algorithm (TERMINATED) NA NCT04972175 — Safety and Efficacy of BC LisPram (UNKNOWN) PHASE1 Published literature Clinical trial publication Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy (Postgraduate medicine, 2013) Clinical trial publication Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes (The AAPS journal, 2013) Clinical trial publication Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? (The Journal of clinical endocrinology and metabolism, 2010) Clinical trial publication Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2009) Clinical trial publication Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus (Pediatric diabetes, 2009) Randomized controlled trial Properties of pramlintide and insulin upon mixing (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005) Randomized controlled trial Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial (Diabetic medicine : a journal of the British Diabetic Association, 2004) CT.gov search · Cochrane · PubMed	DGIdb	—
PRAMLINTIDE ACETATE Repurposing via CALCR	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT05199714 — A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes (COMPLETED) NA NCT00790699 — Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port (TERMINATED) NA NCT00489645 — Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide (COMPLETED) NA NCT00229658 — An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes (COMPLETED) NCT01269047 — Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (COMPLETED) PHASE4 NCT00502138 — A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes (COMPLETED) PHASE4 NCT01434862 — Pramlintide Combined With Model Predictive Control Algorithm (TERMINATED) NA NCT04972175 — Safety and Efficacy of BC LisPram (UNKNOWN) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
PRAZOSIN Repurposing via ANG	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SALMON CALCITONIN Repurposing via CALCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SIROLIMUS Repurposing via ANG	Small molecule	Approved	Strong	95	8 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT01309022 — Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) (NO_LONGER_AVAILABLE) NCT00464555 — Strategies to Improve Islet Survival (COMPLETED) PHASE2 NCT00286624 — Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation (COMPLETED) PHASE1, PHASE2 NCT00708604 — Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes (COMPLETED) PHASE1 NCT00706420 — Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen (ACTIVE_NOT_RECRUITING) PHASE1 NCT00533442 — Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients (COMPLETED) PHASE2 NCT00160732 — Allogenic Islet Cell Transplantation (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT00679042 — Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (ACTIVE_NOT_RECRUITING) PHASE3 Published literature Clinical trial publication Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005) Clinical trial publication Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen (The New England journal of medicine, 2000) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SITAGLIPTIN Repurposing via CDKAL1	Small molecule	Approved	Strong	95	8 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT01718093 — A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes (COMPLETED) PHASE4 NCT00978796 — Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes (COMPLETED) PHASE4 NCT00813228 — Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals (COMPLETED) PHASE1 NCT02749032 — Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion (COMPLETED) PHASE1 NCT01441232 — A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics (COMPLETED) PHASE1 NCT04409795 — Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study (COMPLETED) PHASE2, PHASE3 NCT01099618 — Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment (COMPLETED) PHASE4 NCT00749190 — BI 10773 add-on to Metformin in Patients With Type 2 Diabetes (COMPLETED) PHASE2 Published literature Clinical trial publication Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study (Diabetes, obesity & metabolism, 2015) Clinical trial publication C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus (JAMA, 2009) CT.gov search · Cochrane · PubMed	DGIdb	—
SULBACTAM Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ANG	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT01309022 — Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) (NO_LONGER_AVAILABLE) NCT00464555 — Strategies to Improve Islet Survival (COMPLETED) PHASE2 NCT00708604 — Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes (COMPLETED) PHASE1 NCT00706420 — Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen (ACTIVE_NOT_RECRUITING) PHASE1 NCT00533442 — Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients (COMPLETED) PHASE2 NCT00679042 — Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (ACTIVE_NOT_RECRUITING) PHASE3 NCT00309231 — Clinical Islet Transplantation Using the Edmonton Protocol (WITHDRAWN) NCT00789308 — Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TALQUETAMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
TARLATAMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
TAZOBACTAM Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TECLISTAMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
TEPLIZUMAB Repurposing via CD3E	Small molecule	Approved	Strong	95	8 trials 5 Cochrane 5 Meta-analysis View evidence Registry trials NCT06338553 — GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab (RECRUITING) EARLY_PHASE1 NCT03751007 — A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) (COMPLETED) PHASE1, PHASE2 NCT07088068 — A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes (RECRUITING) PHASE3 NCT00806572 — Treatment With hOKT3gamma1(Ala-Ala) in T1DM (TERMINATED) PHASE2 NCT07260110 — A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States (RECRUITING) NCT00129259 — Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (COMPLETED) PHASE2 NCT01189422 — Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes (TERMINATED) PHASE1 NCT00920582 — Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus (TERMINATED) PHASE3 Published literature Cochrane review Immunotherapy as a treatment for type 1 diabetes mellitus in children and young adults: A comprehensive systematic review and meta-analysis (PloS one, 2025) Cochrane review Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis (World journal of diabetes, 2024) Cochrane review Effect of Immunotherapy on C-peptide Levels in Patients With Type I Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials (Cureus, 2024) Cochrane review Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials (Diabetes, obesity & metabolism, 2024) Cochrane review Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression (Diabetes, obesity & metabolism, 2023) Meta-analysis Efficacy of teplizumab for treatment of type 1 diabetes: A meta-analysis of randomized controlled trials (Diabetes/metabolism research and reviews, 2024) Meta-analysis Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes (Recent advances in inflammation & allergy drug discovery, 2023) CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
TROGLITAZONE Repurposing via ANG	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DARAPLADIB Repurposing via ANG	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ANG	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
HUMAN CALCITONIN Repurposing via CALCR	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ANG	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

110 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin D3 Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Correction of vitamin D deficiency in a patient results in improved glu… Human Study High-dose VD was associated with improved CAN parameters and reduced aw…	Nutraceutical	Approved	Moderate	20	8 trials 2 RCT View evidence Registry trials NCT00960635 — Immunointervention With Calcitriol in New-Onset Type 1 Diabetes (COMPLETED) PHASE2 NCT01120119 — Efficacy of Calcitriol in Recent Onset Type 1 Diabetes (COMPLETED) PHASE2 NCT01029392 — Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect of Supplementation on Insulin Requirements (COMPLETED) PHASE3 NCT02464033 — EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes (COMPLETED) PHASE2 NCT03345004 — Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (COMPLETED) PHASE2 NCT02352974 — GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1) (COMPLETED) PHASE1 NCT01277913 — The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1 (COMPLETED) PHASE4 NCT05351879 — Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes (COMPLETED) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Omega-3 Fatty Acids Natural product Meta Analysis Effect of omega-3 polyunsaturated fatty acids on cardiovascular outcome… Human Study Dietary intake of omega-3 fatty acids is associated with reduced risk o… Human Study Cocoa extract reduces plasma glucose and insulin in an oral glucose tol…	Nutraceutical	Approved	Moderate	20	8 trials 2 Cochrane 1 Meta-analysis 1 RCT View evidence Registry trials NCT05980026 — Omega-3 Fatty Acids Supplementation Improves Early-stage Diabetic Nephropathy and Subclinical Atherosclerosis in Pediatric Patients With Type 1 Diabetes (COMPLETED) NA NCT03710928 — Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet (RECRUITING) NA NCT00333554 — Nutritional Intervention to Prevent Diabetes (COMPLETED) NA NCT07255326 — Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes (COMPLETED) NA NCT02261545 — The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient (UNKNOWN) PHASE4 NCT02034266 — The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes (COMPLETED) PHASE2 NCT03258840 — EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus (COMPLETED) NA NCT04200391 — Very Low Carbohydrate Diets and Glucagon Response in T1DM (RECRUITING) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Magnesium Natural product Meta-analysis Association between reduced serum levels of magnesium and the presence… Human Study Correction of hypomagnesemia in type 1 diabetic children with oral magn… Human Study Hypomagnesemia is a common problem in adults with T1D, and it was corre…	Nutraceutical	Phase III	Moderate	20	8 trials 1 Meta-analysis 1 Trial pubs View evidence Registry trials NCT03710928 — Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet (RECRUITING) NA NCT01881828 — Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (COMPLETED) PHASE3 NCT02837094 — Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 (COMPLETED) PHASE1 NCT04774224 — Baricitinib in New-onset Type 1 Diabetes (COMPLETED) PHASE2 NCT04200391 — Very Low Carbohydrate Diets and Glucagon Response in T1DM (RECRUITING) NA NCT02045290 — Insulin Clamp Ancillary Study for Assessment of Insulin Resistance (COMPLETED) PHASE3 NCT05899166 — Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes (RECRUITING) NA NCT05067270 — A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus (COMPLETED) PHASE1 Published literature Meta-analysis Association between reduced serum levels of magnesium and the presence of poor glycemic control and complications in type 1 diabetes mellitus: A systematic review and meta-analysis (Diabetes & metabolic syndrome, 2020) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin C Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Correction of vitamin D deficiency in a patient results in improved glu… Human Study Intralymphatic glutamic acid decarboxylase with vitamin D supplementati…	Nutraceutical	Approved	Moderate	20	8 trials 4 Trial pubs View evidence Registry trials NCT00055042 — Laser and Antioxidant Treatment of Diabetic Macular Edema (COMPLETED) PHASE1 NCT06640478 — A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (ACTIVE_NOT_RECRUITING) NA NCT01319734 — Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus (UNKNOWN) PHASE1 NCT01350102 — The Relationship of Hemoglobin A1c and Diabetic Wound Healing (TERMINATED) PHASE4 NCT00786019 — Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes (COMPLETED) NA NCT00858273 — Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B (COMPLETED) NA NCT03920397 — Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus (COMPLETED) NA NCT02019186 — Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Zinc Natural product Clinical trial publication Effect of daily zinc supplementation for 12 weeks on serum thyroid auto… Clinical trial publication Improved glycemic control either alone, or combined with antioxidant su… Clinical trial publication Anti-Zinc Transporter Protein 8 Antibody Testing Is Not Informative in…	Nutraceutical	Phase I	Moderate	20	4 trials 2 Cochrane 3 Trial pubs 2 RCT View evidence Registry trials NCT01319734 — Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus (UNKNOWN) PHASE1 NCT06791330 — Genome-wide Association Study of Different Types of Diabetes and Construction of Genetic Risk Score (COMPLETED) NCT00858273 — Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B (COMPLETED) NA NCT04234867 — Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) (TERMINATED) PHASE1 Published literature Clinical trial publication Effect of daily zinc supplementation for 12 weeks on serum thyroid auto-antibody levels in children and adolescents with autoimmune thyroiditis - a randomized controlled trial (Journal of pediatric endocrinology & metabolism : JPEM, 2024) Clinical trial publication Improved glycemic control either alone, or combined with antioxidant supplementation, fails to restore blood glutathione or markers of oxidative stress in adolescents with poorly controlled type 1 diabetes (Nutrition research (New York, N.Y.), 2023) Clinical trial publication Anti-Zinc Transporter Protein 8 Antibody Testing Is Not Informative in Routine Prediabetes Screening in Young Patients with Autoimmune Thyroiditis and Celiac Disease (Hormone research in paediatrics, 2016) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin D3 Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Correction of vitamin D deficiency in a patient results in improved glu… Human Study Intralymphatic glutamic acid decarboxylase with vitamin D supplementati…	Nutraceutical	Approved	Emerging	19	8 trials 2 RCT View evidence Registry trials NCT00960635 — Immunointervention With Calcitriol in New-Onset Type 1 Diabetes (COMPLETED) PHASE2 NCT01120119 — Efficacy of Calcitriol in Recent Onset Type 1 Diabetes (COMPLETED) PHASE2 NCT01029392 — Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect of Supplementation on Insulin Requirements (COMPLETED) PHASE3 NCT02464033 — EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes (COMPLETED) PHASE2 NCT03345004 — Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (COMPLETED) PHASE2 NCT02352974 — GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1) (COMPLETED) PHASE1 NCT01277913 — The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1 (COMPLETED) PHASE4 NCT05351879 — Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes (COMPLETED) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, Examine.com	PubChem Examine.com
Vitamin C Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Correction of vitamin D deficiency in a patient results in improved glu… Human Study Intralymphatic glutamic acid decarboxylase with vitamin D supplementati…	Nutraceutical	Approved	Emerging	19	8 trials 4 Trial pubs View evidence Registry trials NCT00055042 — Laser and Antioxidant Treatment of Diabetic Macular Edema (COMPLETED) PHASE1 NCT06640478 — A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (ACTIVE_NOT_RECRUITING) NA NCT01319734 — Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus (UNKNOWN) PHASE1 NCT01350102 — The Relationship of Hemoglobin A1c and Diabetic Wound Healing (TERMINATED) PHASE4 NCT00786019 — Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes (COMPLETED) NA NCT00858273 — Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B (COMPLETED) NA NCT03920397 — Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus (COMPLETED) NA NCT02019186 — Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, Examine.com	PubChem Examine.com
Omega-3 Fatty Acids Natural product Meta Analysis Effect of omega-3 polyunsaturated fatty acids on cardiovascular outcome… Human Study Cocoa extract reduces plasma glucose and insulin in an oral glucose tol… Human Study Dietary intake of omega-3 fatty acids is associated with reduced risk o…	Nutraceutical	Approved	Emerging	19	8 trials 2 Cochrane 1 Meta-analysis 1 RCT View evidence Registry trials NCT05980026 — Omega-3 Fatty Acids Supplementation Improves Early-stage Diabetic Nephropathy and Subclinical Atherosclerosis in Pediatric Patients With Type 1 Diabetes (COMPLETED) NA NCT03710928 — Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet (RECRUITING) NA NCT00333554 — Nutritional Intervention to Prevent Diabetes (COMPLETED) NA NCT07255326 — Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes (COMPLETED) NA NCT02261545 — The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient (UNKNOWN) PHASE4 NCT02034266 — The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes (COMPLETED) PHASE2 NCT03258840 — EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus (COMPLETED) NA NCT04200391 — Very Low Carbohydrate Diets and Glucagon Response in T1DM (RECRUITING) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Magnesium Natural product Meta-analysis Association between reduced serum levels of magnesium and the presence… Human Study Correction of hypomagnesemia in type 1 diabetic children with oral magn… Human Study Low serum magnesium may be included in pathogenesis of poor glycemic co…	Nutraceutical	Phase III	Emerging	19	8 trials 1 Meta-analysis 1 Trial pubs View evidence Registry trials NCT03710928 — Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet (RECRUITING) NA NCT01881828 — Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (COMPLETED) PHASE3 NCT02837094 — Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 (COMPLETED) PHASE1 NCT04774224 — Baricitinib in New-onset Type 1 Diabetes (COMPLETED) PHASE2 NCT04200391 — Very Low Carbohydrate Diets and Glucagon Response in T1DM (RECRUITING) NA NCT02045290 — Insulin Clamp Ancillary Study for Assessment of Insulin Resistance (COMPLETED) PHASE3 NCT05899166 — Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes (RECRUITING) NA NCT05067270 — A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus (COMPLETED) PHASE1 Published literature Meta-analysis Association between reduced serum levels of magnesium and the presence of poor glycemic control and complications in type 1 diabetes mellitus: A systematic review and meta-analysis (Diabetes & metabolic syndrome, 2020) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Zinc Natural product Clinical trial publication Effect of daily zinc supplementation for 12 weeks on serum thyroid auto… Clinical trial publication Improved glycemic control either alone, or combined with antioxidant su… Clinical trial publication Anti-Zinc Transporter Protein 8 Antibody Testing Is Not Informative in…	Nutraceutical	Phase I	Emerging	19	4 trials 2 Cochrane 3 Trial pubs 2 RCT View evidence Registry trials NCT01319734 — Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus (UNKNOWN) PHASE1 NCT06791330 — Genome-wide Association Study of Different Types of Diabetes and Construction of Genetic Risk Score (COMPLETED) NCT00858273 — Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B (COMPLETED) NA NCT04234867 — Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) (TERMINATED) PHASE1 Published literature Clinical trial publication Effect of daily zinc supplementation for 12 weeks on serum thyroid auto-antibody levels in children and adolescents with autoimmune thyroiditis - a randomized controlled trial (Journal of pediatric endocrinology & metabolism : JPEM, 2024) Clinical trial publication Improved glycemic control either alone, or combined with antioxidant supplementation, fails to restore blood glutathione or markers of oxidative stress in adolescents with poorly controlled type 1 diabetes (Nutrition research (New York, N.Y.), 2023) Clinical trial publication Anti-Zinc Transporter Protein 8 Antibody Testing Is Not Informative in Routine Prediabetes Screening in Young Patients with Autoimmune Thyroiditis and Celiac Disease (Hormone research in paediatrics, 2016) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin E Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Benfotiamine and alpha-lipoic acid normalises complication-causing path… Human Study Correction of vitamin D deficiency in a patient results in improved glu…	Nutraceutical	Approved	Emerging	19	8 trials View evidence Registry trials NCT00055042 — Laser and Antioxidant Treatment of Diabetic Macular Edema (COMPLETED) PHASE1 NCT06640478 — A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (ACTIVE_NOT_RECRUITING) NA NCT01973400 — Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus (COMPLETED) PHASE3 NCT00858273 — Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B (COMPLETED) NA NCT01098994 — Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes (COMPLETED) NA NCT02019186 — Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes (COMPLETED) PHASE4 NCT03436992 — Estrogen and Diabetes (COMPLETED) NA NCT00638560 — Changes of Biomarkers in Response to Training and Antioxidant Treatment (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Saffron Natural product Human Study A probiotic supplement with saffron extract improves serum triglyceride…	Botanical	Preclinical	Moderate	17	1 trials View evidence Registry trials NCT05933460 — Crocus Sativus Extract Impact in Metabolic Control of Patients With Diabetes Mellitus Type 1 (COMPLETED) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Coenzyme Q10 Natural product	Nutraceutical	Phase II	Moderate	17	2 trials 3 Trial pubs 2 RCT View evidence Registry trials NCT03111433 — Efficacy of Coenzyme q10 in Pediatrics With Type 1 Diabetes Mellitus (COMPLETED) PHASE2 NCT06361680 — Effect of Coenzyme Q10 on Diabetic Children (UNKNOWN) EARLY_PHASE1 CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Chromium Natural product	Nutraceutical	Preclinical	Moderate	17	1 trials View evidence Registry trials NCT01709123 — Effects of Micronutrient (Chromium) Supplementation on Diabetes (COMPLETED) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
L-Carnitine Natural product	Amino acid	Preclinical	Moderate	17	2 trials View evidence Registry trials NCT00351234 — Carnitine Levels and Carnitine Supplementation in Type I Diabetes (COMPLETED) NCT03660293 — Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs (COMPLETED) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Probiotics Natural product Clinical trial publication Supplementation of High-Strength Oral Probiotics Improves Immune Regula… Clinical trial publication The effect of oral probiotics on glycated haemoglobin levels in childre… Clinical trial publication Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32…	Probiotic	Approved	Emerging	16	8 trials 3 Cochrane 5 Trial pubs View evidence Registry trials NCT03423589 — Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics (COMPLETED) NA NCT03961854 — Lactobacillus Johnsonii in Children and Adolescents With T1D (COMPLETED) PHASE2 NCT03556631 — Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes (COMPLETED) PHASE4 NCT07373392 — Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus (NOT_YET_RECRUITING) NA NCT04014660 — Prevention av Autoimmunitet Med Laktobaciller (COMPLETED) NA NCT04141761 — Probiotics in Newly Diagnosed T1D (ACTIVE_NOT_RECRUITING) PHASE2 NCT04335656 — Reducing Innate Inflammation in New Onset Type 1 Diabetes (ACTIVE_NOT_RECRUITING) PHASE2 NCT04635670 — Effects of Probiotics and Fibers on Albuminuria in Persons With Type 1 Diabetes (COMPLETED) NA Published literature Clinical trial publication Supplementation of High-Strength Oral Probiotics Improves Immune Regulation and Preserves Beta Cells among Children with New-Onset Type 1 Diabetes Mellitus: A Randomised, Double-Blind Placebo Control Trial (Indian journal of pediatrics, 2025) Clinical trial publication The effect of oral probiotics on glycated haemoglobin levels in children with type 1 diabetes mellitus - a randomized clinical trial (Pediatric endocrinology, diabetes, and metabolism, 2023) Clinical trial publication Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus (Frontiers in endocrinology, 2022) Clinical trial publication A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study (Pediatric diabetes, 2021) Clinical trial publication Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type 1 diabetes--the PRODIA study (Annals of the New York Academy of Sciences, 2006) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	—
Curcumin Natural product Animal Study A novel curcumin derivative regenerates pancreatic islets in experiment…	Food compound	Phase III	Emerging	16	3 trials View evidence Registry trials NCT02529982 — Curcumin Supplementation and Patients With Type 2 Diabetes (COMPLETED) NA NCT02529969 — Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes (UNKNOWN) PHASE2, PHASE3 NCT01646047 — Diabetes Visual Function Supplement Study (COMPLETED) NA CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Iron Natural product Human Study Conventional insulin therapy plus probiotics supplementation attenuated… Human Study D-chiro-inositol plus folic acid oral supplementation can improve metab… Human Study Ginger supplementation is an effective treatment for type 2 diabetes.	Nutraceutical	Phase II	Emerging	16	7 trials 1 Cochrane 1 Meta-analysis View evidence Registry trials NCT00453817 — Islet of Langerhans Graft Monitoring by Magnetic Resonance Imaging (TERMINATED) PHASE1 NCT01050166 — MRI Imaging of Labeled Human Islets Transplanted Into the Liver (COMPLETED) NCT00129259 — Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (COMPLETED) PHASE2 NCT04956263 — A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes (COMPLETED) PHASE2 NCT06443593 — Effect of Micronutrient Supplementation on Nerve Conduction Velocity in T1D- RCT (UNKNOWN) NA NCT01521520 — Imaging of Type 1 Diabetes Progression (UNKNOWN) NCT06664099 — Comparison of Weight Loss and Nutritional Deficiency After One Anastomosis Gastric Bypass at 150, 170, and 200 cm From the Duodenojejunal Junction (COMPLETED) NA CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Coenzyme Q10 Natural product Coenzyme Q10 administration has no effect on sICAM-1 and metabolic para… Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, ins…	Nutraceutical	Phase II	Emerging	13	2 trials 3 Trial pubs 2 RCT View evidence Registry trials NCT03111433 — Efficacy of Coenzyme q10 in Pediatrics With Type 1 Diabetes Mellitus (COMPLETED) PHASE2 NCT06361680 — Effect of Coenzyme Q10 on Diabetic Children (UNKNOWN) EARLY_PHASE1 CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
L-Carnitine Natural product Comparative study of the efficacy of captopril, simvastatin, and L-carn…	Amino acid	Phase I	Emerging	13	2 trials View evidence Registry trials NCT00351234 — Carnitine Levels and Carnitine Supplementation in Type I Diabetes (COMPLETED) NCT03660293 — Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs (COMPLETED) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Chromium Natural product Polycystic ovary syndrome and type 1 diabetes - the current state of kn… Determinants Related to Oxidative Stress Parameters in Pediatric Patien… THE CONTENT OF MICROELEMENTS IN BLOOD SERUM AND ERYTHROCYTES IN CHILDRE…	Nutraceutical	Phase I	Emerging	10	1 trials View evidence Registry trials NCT01709123 — Effects of Micronutrient (Chromium) Supplementation on Diabetes (COMPLETED) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Saffron Natural product Human Study A probiotic supplement with saffron extract improves serum triglyceride…	Botanical	Phase I	Emerging	10	1 trials View evidence Registry trials NCT05933460 — Crocus Sativus Extract Impact in Metabolic Control of Patients With Diabetes Mellitus Type 1 (COMPLETED) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Benfotiamine Natural product Human Study Benfotiamine and alpha-lipoic acid normalises complication-causing path…	Nutraceutical	Preclinical	Moderate	10	—	Examine.com	Examine.com
Bromelain Natural product	Nutraceutical	Preclinical	Moderate	10	—	Examine.com	Examine.com
Fiber Natural product Human Study Total dietary fiber reveals modest inverse associations with poor glyce…	Nutraceutical	Preclinical	Moderate	10	—	Examine.com	Examine.com
Ginger Natural product Human Study Ginger is an aldose reductase inhibitor which may have contribute to th… Human Study Ginger supplementation is an effective treatment for type 2 diabetes. Animal Study Ameliorative Potentials of Ginger (Z. officinale Roscoe) on Relative Or…	Botanical	Preclinical	Emerging	10	—		PubChem
Garlic Natural product Animal Study A vanadium/garlic complex was found to have potent antidiabetic activit… Animal Study Allicin could decrease blood glucose level, improve islet structure and… Animal Study An aqueous garlic extract has beneficial effects on inflammation and ox…	Food compound	Preclinical	Emerging	10	—		PubChem
Folate Natural product Human Study D-chiro-inositol plus folic acid oral supplementation can improve metab…	Nutraceutical	Preclinical	Emerging	10	—		PubChem
Vitamin B12 Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Correction of vitamin D deficiency in a patient results in improved glu… Human Study High-dose VD was associated with improved CAN parameters and reduced aw…	Nutraceutical	Preclinical	Emerging	10	—		PubChem
3-aminopropionic Acid Natural product Meta Analysis The beta-casein A1 protein variant of cow's milk may contribute to… Meta Analysis The consumption of cow milk A1 beta-casein is associated with increased… Human Study Breastfeeding within the first 4 months of life prevents the generation…	Food compound	Preclinical	Moderate	10	—	Examine.com	PubChem Examine.com
D-Ribose Natural product	Food compound	Preclinical	Moderate	10	—	Examine.com	PubChem Examine.com
Olive Oil Natural product Human Study Effect of extra virgin olive oil and butter on endothelial function in… Human Study A probiotic supplement with saffron extract improves serum triglyceride… Human Study Cocoa extract reduces plasma glucose and insulin in an oral glucose tol…	Nutraceutical	Preclinical	Emerging	10	—		—
Curcumin Natural product Animal Study A novel curcumin derivative regenerates pancreatic islets in experiment…	Food compound	Phase III	Emerging	7	3 trials View evidence Registry trials NCT02529982 — Curcumin Supplementation and Patients With Type 2 Diabetes (COMPLETED) NA NCT02529969 — Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes (UNKNOWN) PHASE2, PHASE3 NCT01646047 — Diabetes Visual Function Supplement Study (COMPLETED) NA CT.gov search · Cochrane · PubMed		PubChem
Cinnamon Natural product Habits, Traditions, and Beliefs Associated With the Use of Complementar… A nutraceutical combination of Cinnamomum cassia &Nigella sativa for Ty… [Role of complementary medicine in type 1 diabetes mellitus in two Swis…	Botanical	Preclinical	Emerging	7	—		PubChem
Bitter Melon Natural product Animal Study A cucurbitane type triterpenoid compound from Momordica charantia allev…	Botanical	Preclinical	Emerging	7	—		—
Alpha-Lipoic Acid Natural product Human Study Benfotiamine and alpha-lipoic acid normalises complication-causing path… Human Study The role of oral alpha-lipoic acid as an adjuvant antioxidant therapy i… Animal Study Acorus calamus has insulin releasing and alpha-glucosidase inhibitory a…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Resveratrol Natural product Human Study Resveratrol inhibits cellular oxidative stress in monocytes cultured fr…	Food compound	Preclinical	Emerging	7	—		PubChem
Berberine Natural product The effect(s) of berberine from Berberis vulgaris L. (Berberidaceae) on… Berberine treatment inhibits ferroptosis in NIT-1 murine pancreatic cel… Berberine Regulates GPX4 to Inhibit Ferroptosis of Islet β Cells	Botanical	Preclinical	Emerging	7	—		PubChem
Fenugreek Natural product Human Study Fenugreek seeds have a significant therapeutic effect on blood glucose…	Botanical	Preclinical	Emerging	7	—		—
Niacin Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Correction of vitamin D deficiency in a patient results in improved glu… Human Study High-dose VD was associated with improved CAN parameters and reduced aw…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Astragalus Natural product Formononetin, a bioactive isoflavonoid constituent from Astragalus memb… Chinese medicine Ginseng and Astragalus granules ameliorate autoimmune… Integrative traditional Chinese medicine therapy reduces the risk of di…	TCM herb	Preclinical	Emerging	7	—		—
Echinacea Natural product Meta Analysis Dietary consumption of Echinacea by mice afflicted with autoimmune (typ…	Botanical	Preclinical	Emerging	7	—		—
Cordyceps Natural product Animal Study A hybridized strain of Cordyceps (Paecilomyces hepiali) may prevent aut…	Mushroom	Preclinical	Emerging	7	—		—
Cannabidiol Natural product Animal Study Abnormal cannabidiol ameliorates inflammation preserving pancreatic bet…	Food compound	Preclinical	Emerging	2	—		PubChem
(Z)-octadec-11-enoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Oyster mushroom reduced blood glucose and cholesterol in diabetic subje…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(9Z,12Z)-octadeca-9,12-dienoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Oyster mushroom reduced blood glucose and cholesterol in diabetic subje…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
undecanoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Oyster mushroom reduced blood glucose and cholesterol in diabetic subje…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
caprylic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Oyster mushroom reduced blood glucose and cholesterol in diabetic subje…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
3-methylbutyric acid [(2S,3R,4R)-2-(4-hydroxy-3-methoxy-phenyl)-4-vanillyl-tetrahydrofuran-3-yl]methyl ester Natural product Human Study 1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic to… Human Study Oyster mushroom reduced blood glucose and cholesterol in diabetic subje…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Bortezomib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Staurosporinone Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
3-aminopropionic Acid Natural product Meta Analysis The beta-casein A1 protein variant of cow's milk may contribute to… Meta Analysis The consumption of cow milk A1 beta-casein is associated with increased… Human Study Breastfeeding within the first 4 months of life prevents the generation…	Food compound	Preclinical	Emerging	0	—	Examine.com	PubChem Examine.com
D-Ribose Natural product D-ribose is elevated in T1DM patients and can be involved in the onset…	Food compound	Preclinical	Emerging	0	—	Examine.com	PubChem Examine.com
(2S)-2-(3-aminopropanoylamino)-3-(1H-imidazol-5-yl)propionic acid Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
Cyclohexane-1,2,3,4,5,6-Hexol Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
Amaranth Natural product Human Study Cocoa flavanols reverse vascular dysfunction in diabetics. Animal Study Amaranth grain and oil may contribute to correcting high blood sugar an…	Nutraceutical	Preclinical	Emerging	0	—		—
Ginsenosides Natural product Human In Vitro Cytoprotective effects of ginsenoside Rd on apoptosis-associated cell d…	Nutraceutical	Preclinical	Emerging	0	—		—
Camel Milk Natural product Human Study Camel milk had significant beneficial effects in patients with diabetic… Human Study Camel milk is safe and efficacious in improving long-term glycemic cont… Human Study Daily ingestion of camel milk can aid metabolic control in young type 1…	Nutraceutical	Preclinical	Emerging	0	—		—
Diosmin Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Banana Natural product Animal Study, In Vitro Study A root extract of wild banana is capable of exhibiting significant anti…	Nutraceutical	Preclinical	Emerging	0	—		—
Fermented Foods and Beverages Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Astaxanthin Natural product Effect of astaxanthin on metabolic cataract in rats with type 1 diabete…	Food compound	Preclinical	Emerging	0	—		PubChem
Coriandrum Sativum Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Cinnamaldehyde Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Cocoa Natural product Human Study Cocoa flavanols intake benefits cognitive function in type 1 diabetes. Human Study Cocoa flavanols reverse vascular dysfunction in diabetics. Human Study Cocoa extract reduces plasma glucose and insulin in an oral glucose tol…	Nutraceutical	Preclinical	Emerging	0	—		—
Dates Natural product Human Study Date consumption (and mainly the Hallawi variety) by healthy subjects,…	Nutraceutical	Preclinical	Emerging	0	—		—
Honey Natural product Human Study Honey may be an ideal sugar substitute in patients with type 1 diabetes… Human Study Long-term consumption of honey might have positive effects on the metab…	Nutraceutical	Preclinical	Emerging	0	—		—
Flavonoids Natural product Animal Study, In Vitro Study Icariin ameliorates endothelial dysfunction in type 1 diabetes. Animal Study, In Vitro Study The synergistic influence of polyflavonoids from Citrus aurantifolia on…	Nutraceutical	Preclinical	Emerging	0	—		—
Plantain Natural product Animal Study A composite extract of plantain (Musa paradisiaca) and Coccinia indica… Animal Study An extract of plantain has blood sugar lowering effects in diabetic mic…	Nutraceutical	Preclinical	Emerging	0	—		—
Medicinal Mushrooms Natural product Animal Study Administration of medicinal mushrooms under experimental diabetes showe…	Nutraceutical	Preclinical	Emerging	0	—		—
Agrimony Natural product Animal Study Agrimony exhibits antihyperglycaemic, insulin-releasing and insulin-lik…	Nutraceutical	Preclinical	Emerging	0	—		—
Alfalfa Natural product Animal Study Alfalfa demonstrates blood sugar lowering, insulin-releasing and insuli…	Nutraceutical	Preclinical	Emerging	0	—		—
Avocado Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Artesunate Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Blueberry Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Chlorella (Algae) Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Chlorogenic Acid Natural product	Food compound	Preclinical	Emerging	0	—		PubChem
Chrysin Natural product	Food compound	Preclinical	Emerging	0	—		PubChem
Curry Leaves Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Mustard Greens Natural product	Nutraceutical	Preclinical	Emerging	0	—		—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.